title: Improved results with combined donor-specific transfusion (DST) and sequential therapy protocol.
abstract: A combined DST-sequential CyA therapy protocol has been described that results in optimum graft survival for 1- and 2-haplotype mismatched living related donor-recipient combinations. In addition to the excellent graft survival obtained through 4 years, lower prednisone and CyA dosage levels are achieved with significantly decreased infection rates during the posttransplant period.
authors.affiliation: Transplant Service, University of California, San Francisco 94143-0116.
authors.forename: O
authors.initials: O
authors.lastname: Salvatierra
authors.forename: J
authors.initials: J
authors.lastname: McVicar
authors.forename: J
authors.initials: J
authors.lastname: Melzer
authors.forename: W
authors.initials: W
authors.lastname: Amend
authors.forename: F
authors.initials: F
authors.lastname: Vincenti
authors.forename: S
authors.initials: S
authors.lastname: Tomlanovich
authors.forename: R
authors.initials: R
authors.lastname: Husing
authors.forename: J
authors.initials: J
authors.lastname: Rabkin
authors.forename: M
authors.initials: M
authors.lastname: Garovoy
mesh_terms: D001803:Blood Transfusion; D003141:Communicable Diseases / Q000150:complications; D004305:Dose-Response Relationship, Drug; D006084:Graft Rejection; D006085:Graft Survival; D006239:Haplotypes; D006648:Histocompatibility; D006801:Humans; D006973:Hypertension / Q000150:complications; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation / Q000276:immunology / Q000379:methods*; D011241:Prednisone / Q000008:administration & dosage; D016019:Survival Analysis; D014019:Tissue Donors
chemical_list: D011241:Prednisone